Dayao Zhao
Algemeen Directeur bij AffaMed Therapeutics
Oorsprong van het eerstegraads netwerk van Dayao Zhao
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Affamed Therapeutics (Us), Inc.
 Affamed Therapeutics (Us), Inc. Pharmaceuticals: MajorHealth Technology Part of AffaMed Therapeutics, Affamed Therapeutics (US), Inc. is a clinical stage biopharmaceutical company based in New York, NY. The company focuses on developing and commercializing pharmaceutical, digital, and surgical products to address critical unmet medical needs in ophthalmological, neurological, and psychiatric disorders for patients worldwide. The CEO of the company is Dayao Zhao.
4
| Subsidiary | Pharmaceuticals: Major | 4 |
AffaMed Therapeutics
 AffaMed Therapeutics Pharmaceuticals: MajorHealth Technology AffaMed Therapeutics is a Chinese company focused on providing innovative treatments to patients. The company is based in Shanghai, CN. The company's mission and vision are centered around improving patient access to these treatments. The company has a pipeline of products in development to achieve this goal. and has subsidiaries in United States and Hong Kong. The CEO of the company is Dayao Zhao.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Dayao Zhao via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
SK Holdings, Inc.
 SK Holdings, Inc. BroadcastingConsumer Services Part of Match Group, Inc., SK Holdings, Inc. is a company based in New York, NY. | Broadcasting | Corporate Officer/Principal | |
| CHINA NEPSTAR CHAIN DRUGSTORE LTD.(ADR) | Drugstore Chains | Investor Relations Contact | |
Burrill LLC
 Burrill LLC Investment ManagersFinance Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California. | Investment Managers | Private Equity Investor | |
| Nanyang Technological University | College/University | Undergraduate Degree | |
| Icahn School of Medicine at Mount Sinai | College/University | Doctorate Degree | |
| Weill Cornell Medical College | College/University | Doctorate Degree | |
| GENEXINE, INC. | Biotechnology | Chief Executive Officer | |
Merck Sharp & Dohme Corp.
 Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Themes Investment Management Ltd.
 Themes Investment Management Ltd. Investment ManagersFinance Themes Investment Management Ltd is a private equity firm founded in 2009. The firm is headquartered in Hong Kong. | Investment Managers | Corporate Officer/Principal | |
| FAR EAST HORIZON LIMITED | Finance/Rental/Leasing | Corporate Officer/Principal | |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
 Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Medical Specialties | Director/Board Member | |
| Zhongshan Hospital Fudan University | College/University | Undergraduate Degree | |
| HUGEL, INC. | Biotechnology | Director/Board Member | |
Korea Evaluation Institute of Industrial Technology
 Korea Evaluation Institute of Industrial Technology Miscellaneous Commercial ServicesCommercial Services Korea Evaluation Institute of Industrial Technology operates as a research institute to develop technology for domestic industries. The company is based in Daegu, South Korea. The South Korean company is ultimately controlled by the Government of South Korea. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| BEIGENE, LTD. | Pharmaceuticals: Major | Director/Board Member | |
I-Mab Bio-tech (Tianjin) Co. Ltd.
 I-Mab Bio-tech (Tianjin) Co. Ltd. BiotechnologyHealth Technology I-Mab Bio-tech (Tianjin) Co., Ltd. engages in the research and development of medicine and biological products. Its business activities include investment information consultation, and health information services. The company was founded on April 19, 2012 and is headquartered in Tianjin, China. | Biotechnology | Director/Board Member | |
| C-Bridge Capital Partners LLC | Corporate Officer/Principal | ||
CBC Group (Singapore) Pte. Ltd.
 CBC Group (Singapore) Pte. Ltd. Investment ManagersFinance CBC Group (Singapore) Pte. Ltd.(CBC Group) is a private equity firm founded in 2014 by Wei Fu. The firm is headquartered in Singapore with additional offices in New York, Hong Kong, Shanghai and Beijing and is wholly owned by CBC Group Investment Management Ltd. | Investment Managers | Private Equity Investor Chief Executive Officer | |
| EVEREST MEDICINES LIMITED | Pharmaceuticals: Major | Director/Board Member Chairman | |
| ASCLETIS PHARMA INC. | Biotechnology | Director/Board Member | |
I-MAB Biopharma Co., Ltd.
 I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Biotechnology | Director/Board Member | |
| CBC Group Co., Ltd. | Chief Executive Officer | ||
PT Kalbe Genexine Biologics
 PT Kalbe Genexine Biologics BiotechnologyHealth Technology PT Kalbe Genexine Biologics is a clinical-stage biotech company based in Jakarta, Indonesia. The Indonesian company specializes in licensing novel biologics and biosimilars in oncology and high-specialty therapeutic areas, as well as contract manufacturing. The company was founded in 2016 and is backed by Kalbe and Genexine, as well as US private equity giant General. The CEO is Sie Djohan. | Biotechnology | Director/Board Member | |
| I-MAB | Pharmaceuticals: Major | Director/Board Member | |
| C-Bridge Capital Investment Management Ltd. | Chief Executive Officer | ||
| Standard Chartered Business Consulting Beijing Co. Ltd. | Corporate Officer/Principal | ||
Everest Medicines II Ltd.
 Everest Medicines II Ltd. Pharmaceuticals: MajorHealth Technology Everest Medicines II Ltd. develops and commercializes pharmaceutical products. The private company is based in Road Town, Cayman Islands. | Pharmaceuticals: Major | Director/Board Member | |
| Everest Medicines II HK Ltd. | Director/Board Member | ||
| Everest Medicines (Singapore) Pte Ltd. | Director/Board Member | ||
| Everonc Medicines Ltd. | Director/Board Member | ||
| Everonc Medicines, Inc. | Director/Board Member | ||
| Everest Medicines II BVI Ltd. | Director/Board Member | ||
InxMed Biotechnology Nanjing Co., Ltd.
 InxMed Biotechnology Nanjing Co., Ltd. BiotechnologyHealth Technology InxMed Biotechnology Nanjing Co., Ltd. is a clinical-stage biotech company established in 2018, dedicated to developing innovative therapies to overcome treatment resistance, especially anti PD-1/PD-L1 resistance. InxMed is based in Nanjing, China, and has teams located in Shanghai and Beijing, with hubs in San Francisco and Melbourne. The Chinese company's innovations are inspired by patients and driven by in-depth understanding of disease biology and pharmacology. InxMed has raised tens of millions of US dollars in series A round financing and has an integrated high-caliber research and clinical development team across China, the US, and Australia. The company has built a unique innovative pipeline through its own discovery research and development and collaborative research and development. The company was founded in 2018 by Fei Cao and Zai Qi Wang, with Zai Qi Wang serving as the CEO since then. | Biotechnology | Director/Board Member | |
C-Bridge Capital LLC
 C-Bridge Capital LLC Investment ManagersFinance C-Bridge Capital LLC (C-Bridge Capital) is a venture capital subsidiary of CBC Group founded in 2019 by Fu Wei. The firm is headquartered in New York.. | Investment Managers | Private Equity Investor | |
C-Bridge Capital GP IV Ltd.
 C-Bridge Capital GP IV Ltd. Financial ConglomeratesFinance Part of CBC Group Investment Management Ltd., C-Bridge Capital GP IV Ltd. provides investment services. | Financial Conglomerates | Director/Board Member | |
Portola Capital Partners
 Portola Capital Partners Investment ManagersFinance Portola Capital Partners is a private equity firm founded in 1992. The firm is headquartered in Silicon Valley, California. | Investment Managers | Private Equity Investor |
Statistieken
Internationaal
| Verenigde Staten | 14 |
| China | 10 |
| Kaaimaneilanden | 6 |
| Singapore | 4 |
| Zuid-Korea | 4 |
Sectoraal
| Health Technology | 17 |
| Finance | 8 |
| Consumer Services | 6 |
| Retail Trade | 2 |
| Commercial Services | 2 |
Operationeel
| Director/Board Member | 23 |
| Corporate Officer/Principal | 12 |
| Private Equity Investor | 4 |
| Chief Executive Officer | 4 |
| Chairman | 3 |
Sterkste connecties
| Insiders | |
|---|---|
| Wei Fu | 21 |
| Michael Keyoung | 17 |
| Ji Li | 6 |
| Lucia Qian | 2 |
| Annie Lee | 1 |
| Vijay Karwal | 1 |
- Beurs
- Insiders
- Dayao Zhao
- Bedrijfsconnecties
